Your browser doesn't support javascript.
loading
Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy.
Zhang, Weinan; He, Zhiqiang; Liang, Fucheng; Gong, Jie; Tan, Liuchang; Yang, Juan; Song, Siji; Xie, Luoyingzi; Lu, Yuangang.
Afiliación
  • Zhang W; Department of Plastic and Cosmetic Surgery, Army Medical Center of PLA, Amy Medical University, No. 10, Daping Changjiang Branch Road, Yuzhong District, Chongqing, China.
  • He Z; Department of Plastic and Cosmetic Surgery, Chongqing Contemporary Plastic Surgery Hospital, Chongqing, China.
  • Liang F; Department of Plastic and Cosmetic Surgery, Army Medical Center of PLA, Amy Medical University, No. 10, Daping Changjiang Branch Road, Yuzhong District, Chongqing, China.
  • Gong J; School of Clinical Medicine, Chongqing Medical University, Chongqing, China.
  • Tan L; Department of Plastic and Cosmetic Surgery, Army Medical Center of PLA, Amy Medical University, No. 10, Daping Changjiang Branch Road, Yuzhong District, Chongqing, China.
  • Yang J; Department of Digestion, The 535th Hospital of the People's Liberation Army, Huaihua, Hunan, China.
  • Song S; Department of Urology, First Affiliated Hospital, Army Medical University, Chongqing, China.
  • Xie L; Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, 118 Xingguang Avenue, Liangjiang New District, Yubei District, Chongqing, China. xieluoyingzi@163.com.
  • Lu Y; Department of Plastic and Cosmetic Surgery, Army Medical Center of PLA, Amy Medical University, No. 10, Daping Changjiang Branch Road, Yuzhong District, Chongqing, China. skin515@163.com.
J Cancer Res Clin Oncol ; 149(18): 16763-16778, 2023 Dec.
Article en En | MEDLINE | ID: mdl-37730912
BACKGROUND: Previously, albendazole (ABZ) has been reported as an anti-parasitic drug rather than anti-tumor drug. Our study aim to investigate whether ABZ also has a potential anti-tumor effect by shaping the tumor immune microenvironment and interrogate whether ABZ could synergize with the PD-L1 blockade. METHODS: C57BL/6 mice (C57) were intravenously injected with B16F10-luciferase (B16-luc) cells to establish a lung metastatic melanoma model and subcutaneously inoculated with B16-luc cells to establish a subcutaneous tumor model. The tumor volume and tumor metastasis loci of the mice were measured by a vernier caliper and in vivo imaging. RNA sequencing was performed to analyze the different genes and pathways of immune cells in the tumors. Flow cytometry and immunofluorescence were used to analyze the different subsets of tumor-infiltrating immune cells. RESULTS: The results suggested that ABZ significantly inhibited lung melanoma metastasis with decreased fluorescence intensity and nodule score and mediated the regression of subcutaneous melanoma in mice with decreased tumor volume. Moreover, RNA sequencing results showed that ABZ regulated the gene expression levels and pathways of immune cells in the tumor microenvironment (TME). Meanwhile, flow cytometry and immunofluorescence showed that the number and percentage of CD8+ T cells, CD4+ T cells, and TH1 cells were enhanced in tumors after ABZ treatment. Furthermore, the combination of ABZ and anti-PD-L1 treatment significantly potentiated anti-tumor efficacy in both lung metastasis and subcutaneous melanoma models and mediated an increase in the percentage of CD8+ T cells, CD4+ T cells, and TH1 cells as compared to the control group. CONCLUSION: ABZ inhibits melanoma growth and metastasis. Moreover, ABZ synergized with PD-L1 blockade mediates tumor regression.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pulmonares / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: J Cancer Res Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Alemania

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Pulmonares / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: J Cancer Res Clin Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Alemania